The Pentagon rolled out a new clinical directive on Wednesday that makes testosterone deficiency screening mandatory for all male service members aged 30 and older, both active‑duty and reservists. The policy, announced by Defense Secretary Pete Hegseth in July, is intended to ensure that troops have the hormonal health needed to perform at their best now and after they leave the uniform.
Why the Screening Matters
Hegseth emphasized that “taking care of your long‑term health means ensuring you remain strong, resilient and capable — not just for your next deployment, but for the rest of your life, so you can thrive long after you take off the uniform.” Testosterone naturally peaks during puberty and begins a gradual decline after the age of 30. Low levels can affect muscle strength, energy, and overall well‑being, which the Pentagon says could impact readiness.
How the Program Works
Under the new guidance, men 30 and older will receive a mandatory blood test for testosterone levels. Younger men will be tested only if they request it or if a clinician identifies warning signs such as persistent fatigue or decreased performance. Service members found to have low testosterone may be referred for further evaluation and, if medically appropriate, offered voluntary hormone replacement therapy.
Women will not be subject to routine testosterone testing, but they will be screened for fatigue and menstrual irregularities that can signal hormonal imbalances. The guidance also outlines when off‑label testosterone prescriptions might be appropriate for post‑menopausal women experiencing unusually low sexual desire.
Balancing Health and Readiness
The Pentagon says the standardized screening and treatment pathways are designed to boost military readiness by identifying and managing hormonal and energy‑availability issues before they become performance‑limiting. However, some endocrinologists and medical experts have voiced concerns that broad testing could lead to unnecessary or potentially harmful treatments, noting a lack of robust evidence that universal screening improves readiness.
The Food and Drug Administration plans to convene a meeting later this month with experts to discuss the medical use of testosterone, indicating that the policy will be closely monitored for safety and efficacy.
What This Means for Service Members
Service members should expect to receive information about the testing process from their medical units. Participation in the screening is mandatory for eligible men, but any subsequent hormone therapy will remain voluntary and contingent on a clinician’s recommendation.
While the policy is focused on health, it also reflects a broader commitment by the Trump administration to prioritize the well‑being of those who serve, reinforcing the principle that a strong, healthy force is essential to national security.
Original reporting: Fox News (HLL/CB) — read the source article.
